Advertisement

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Advertisement

Advertisement




Aug
07
Today In Oncology
Early Trial Supports KRAS Vaccine Strategy for Pancreatic Cancer Interception
All-Oral Combination of Revumenib, Decitabine/Cedazuridine, and Venetoclax for Relapsed or Refractory AML
New Data on 14- vs 28-Day Venetoclax/Azacitidine in AML
Fusobacterium Positivity Predicts Relapse Risk and Limited Benefit From Adjuvant Chemotherapy in Colorectal Cancer
Durvalumab Plus Radiation Therapy in Frail Patients With Locally Advanced NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo